COST-EFFECTIVENESS EVALUATION OF VORICONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS
Invasive Aspergillosis (IA) is a frequent infectious complication of patients with neutropenia. Authors have, for the first time, carried out economic research concerning the use of voriconazole in Russia for the treatment of IA in comparison with alternative methods of treatment. The overall cost was calculated, including the cost of treatment of IA and a number of life-years saved by each group of patients. To evaluate the degree of inaccuracy of the results, sensitivity analyses were performed. It was established that the mode of starting treatment of IA voriconazole was both more effective and less expensive in comparison with the use of caspofungin or amphotericin B lipid complex. The analysis of the full course of treatment of IA has shown that the cost of voriconazole was 1,45 times lower than that of caspofungin and 3,3 times lower than that of amphotericin B lipid complex. The analysis of the alternative, whose efficiency of treatment of IA was equal in all groups, has shown that the economic benefit directly depends on the efficiency of the antimycotic agents. The unilateral analysis of sensitivity proves that the efficiency of expenses of the treatment of IA was more sensitive to a parameter of efficiency than to the change of the expenses connected with the price of medicines. The cost-effect analysis has shown that the use voriconazole for the treatment of IA was the economical basis.